![Oliver Hao](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Oliver Hao
Amministratore Delegato presso Winhealth Pharma Group Co. Ltd.
Profilo
Oliver Hao has worked as a Co-Chief Executive Officer & Director at Winhealth Pharma Group Co. Ltd.
since 2019.
Posizioni attive di Oliver Hao
Società | Posizione | Inizio |
---|---|---|
Winhealth Pharma Group Co. Ltd.
![]() Winhealth Pharma Group Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Winhealth Pharma Group Co. Ltd. is a Chinese innovative biomedical company founded in 2006, providing novel breakthrough therapies to patients with rare diseases and other unmet medical needs. The company is based in Hangzhou, China. Winhealth Pharma Group has established long-term strategic partnerships with dozens of world-leading biotechnology companies, including Roche, Pfizer, Kyowa Kirin, Shionogi, Cumberland Pharmaceutical, and Daiichi-Sankyo. It has built a unique, balanced, and diversified portfolio with numerous orphan drugs and specialty products at commercial and late clinical stages, and will continuously look to bring in more innovative therapies from the globe. The company was founded in 2006 by Cherry Hu and Jack Wang. Jack Wang has been the CEO since 2006. | Amministratore Delegato | 01/01/2019 |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Winhealth Pharma Group Co. Ltd.
![]() Winhealth Pharma Group Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Winhealth Pharma Group Co. Ltd. is a Chinese innovative biomedical company founded in 2006, providing novel breakthrough therapies to patients with rare diseases and other unmet medical needs. The company is based in Hangzhou, China. Winhealth Pharma Group has established long-term strategic partnerships with dozens of world-leading biotechnology companies, including Roche, Pfizer, Kyowa Kirin, Shionogi, Cumberland Pharmaceutical, and Daiichi-Sankyo. It has built a unique, balanced, and diversified portfolio with numerous orphan drugs and specialty products at commercial and late clinical stages, and will continuously look to bring in more innovative therapies from the globe. The company was founded in 2006 by Cherry Hu and Jack Wang. Jack Wang has been the CEO since 2006. | Commercial Services |
- Borsa valori
- Insiders
- Oliver Hao